This article summarized the latest R&D progress of Ezetimibe/Simvastatin, the mechanism of action for Ezetimibe/Simvastatin, and the drug target R&D trends for Ezetimibe/Simvastatin.
ImmunoGen Discloses European Medicines Agency Approval of Mirvetuximab Soravtansine's Marketing Authorization Application for Dealing with Platinum-Resistant Ovarian Cancer.
This article summarized the latest R&D progress of Fam-trastuzumab deruxtecan-NXKI, the mechanism of action for Fam-trastuzumab deruxtecan-NXKI, and the drug target R&D trends for Fam-trastuzumab deruxtecan-NXKI.
TransCode Therapeutics, Inc., an RNA oncology specialist, today announced improved survival rates in mouse models with human glioblastoma multiforme tumors after treatment with their leading candidate, TTX-MC138.
This article summarized the latest R&D progress of Doxycycline Calcium, the Mechanism of Action for Doxycycline Calcium, and the drug target R&D trends for Doxycycline Calcium.
This article summarized the latest R&D progress of Ciltacabtagene autoleucel, the Mechanism of Action for Ciltacabtagene autoleucel, and the drug target R&D trends for Ciltacabtagene autoleucel.
Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.
This article summarized the latest R&D progress of Clocortolone Pivalate, the Mechanism of Action for Clocortolone Pivalate, and the drug target R&D trends for Clocortolone Pivalate.
This article summarized the latest R&D progress of Clofarabine, the Mechanism of Action for Clofarabine, and the drug target R&D trends for Clofarabine.
Recently, Deciphera Pharmaceutical announced the positive top-line results of its investigational drug vimseltinib in the pivotal Phase 3 MOTION trial for patients with Tenosynovial Giant Cell Tumor (TGCT).